U
ncertainty over federal funding for human embryonic stem cell research gained a temporary reprieve recently as a panel of federal appeals court judges ruled 2 -1 to overturn a preliminary injunction.
But the legal issue of whether the National Institutes of Health violated the 15-year-old Dickey -Wicker law, which prohibits using taxpayer dollars for research that destroys or harms human embryos, moved back to the lower court and Chief Judge Royce C. Lamberth for a decision. Lamberth, a judge in the Federal District Court in Washington, imposed the ban last year, briefl y disrupting intramural research on these earliest human cells on the NIH Bethesda campus, as well as grants to medical schools across the country.
"Now the action turns to the main event, the merits of the case," said Anthony Mazzaschi, senior director of scientifi c affairs for the Association of American Medical Colleges, referring to Sherley v. Sebelius . Lamberth gave both sides in the legal action until June 24 to fi le supplemental briefs before he issues a fi nal summary judgment. When that might come is uncertain, although Mazzaschi said he hopes it will happen within the next 6 weeks.
No matter which side prevails, the government or the two scientists -researchers using adult stem cells and who sued the government in August 2009 -the case eventually could come before the U.S. Supreme Court. The scientists, James Sherley, M.D., Ph.D., of the Boston Biomedical Research Institute, and Theresa Deisher, Ph.D., of AVM Biotechnology, won the right to sue on the basis of their claim that adult stem cell research was at a competitive disadvantage to embryonic stem cells for NIH research dollars.
"However the judge rules, whether for NIH or the plaintiffs, it ' s likely to be appealed," said Jennifer Hobin, Ph.D., director of science policy for the Federation of American Societies for Experimental Biology. "I wouldn ' t be at all surprised if it winds up at the Supreme Court."
The Bethesda-based federation, the medical colleges ' association, and the American Association for Cancer Research are all members of the Coalition for the Advancement of Medical Research. The coalition fi led an amicus brief with the court in support of all stem cell researchfrom adult stem cells and induced pluripotent stem cells to human embryonic stem cells. "At some point, science may overtake the need for [using] human embryonic stem cells, but we ' re not there yet," Mazzaschi said. "Our worry is that this issue has created such a toxic research atmosphere, it might affect the career choices of another generation of scientists."
Before sending the case back to Lamberth, the appeals court weighed in on the legal underpinnings of the case, with two of the three judges siding with the government. They called the language of Dickey -Wicker ambiguous and NIH ' s interpretation of the law reasonable; the law bars federal funding "for the destructive act of deriving an ESC [embryonic stem cell] from an embryo" but not for a research project that might use these cells. In a dissenting opinion, however, a third judge, Karen LeCraft Henderson, accused her colleagues of "linguistic jujitsu." Congress intended to stop federal funding of embryonic stem cells "in all of its sequences," she wrote in her dissent.
Current Trials
As the legal battle plays out, NIH ' s current registry of embryonic stem cell lines has At present, the NIH would not approve funding for the stem cell lines in these particular trials, Landis said, because they were developed from preblastocysts, which appear in the fi rst 5 days of embryonic development. "They ' ve learned to take a single blastomere and make embryonic stem cell lines from it," she said, adding that the NIH is proposing changing its guidelines to include cell lines from preblastocyst embryos in the future.
Stem Cells in Cancer
Compared with other diseases, such as Parkinson's disease and heart disease, the potential of human embryonic stem cells to treat cancer attracts much less public attention. But in testimony before Congress last fall, Margaret Foti, M.D., Ph.D., chief executive offi cer of the American Association for Cancer Research, described research using these early cells as "potentially paradigm-shifting" for developing new ways to combat the 200 diseases collectively known as cancer.
And cancer researchers have begun moving promising therapies slowly out of the laboratory toward early clinical trials. Daniel Kaufman, M.D., Ph.D., associate director of the University of Minnesota ' s Stem Cell Institute, and his colleagues, for example, reported in the journal Blood in June 2009 that natural killer cells, derived from human embryonic stem cells, cleared all leukemia cell lines in immune-defi cient mice after several weeks of treatment. In vitro studies also have shown these cells capable of killing additional tumors, including those in prostate, breast, ovarian, and brain cancers, and in multiple myeloma.
"These results suggest the intriguing potential [of these cells] to provide a novel and highly potent resource for cell-mediated adoptive cancer immunotherapy," the researchers wrote. Confi rmatory in vitro studies have been completed, and the University of Minnesota team is now undertaking in vivo studies in mice to ensure that results are not limited to a single cell line.
The next step involves scaling up production of these stem cell -derived natural killer cells, fi nding funding, and "converting this process to conditions suitable for clinical trials," Kaufman said in an e-mail.
Stem cells also lie at the heart of a new experimental treatment for blood cancers. Results of early phase I human trials for myeloproliferative disorders, involving 59 patients, appeared in Cancer Cell in 2008. Catriona Jamieson, M.D., Ph.D., director for stem cell research at the University of California, San Diego ' s Moores Cancer Center and collaborators from Harvard, Stanford, and the Mayo Clinic stopped the characteristic overproduction of blood cells (which sometimes leads to leukemia) by inhibiting the JAK2 signaling pathway.
Before testing in people, Jamieson ' s team put human stem cells engineered to carry a mutant JAK2 gene into mice to see whether too much of this gene would cause disease, which it did. Then, to confi rm that fi nding, they injected stem cells from individuals with these disorders into the mice, with similar results.
"Human embryonic stem cells are giving us essential insight into self-renewal pathways," such as JAK2 or the sonic hedgehog pathway, Jamieson said. "Without understanding this, there ' s no way of knowing how to go after cancer."
In the phase I study, "we saw anemia as the main downside of drug treatment," she said. "But we also saw decreases in overt proliferation." Phase II studies have not yet begun. However, "there ' s big interest," Jamieson said, as protocols work their way through the system.
Meanwhile, an important application of human embryonic stem cells, too often overlooked, holds promise for many diseases, including cancers, according to NIH ' s Landis. "The fi rst thing people think of when they think of human embryonic stem cells is [that] they make replacement cells," she said. "But you can use these cells for drug testing by differentiating them" and then putting a drug of interest through screening tests "to see what will survive." Eventually, instead of using animals, she said, scientists may be able to test routinely for drug toxicity by "creating little liver cells in a dish."
